TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids
Merigolix is an investigational, once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist. Unlike traditional GnRH agonists, which require injection and often lead to an initial hormone surge, Merigolix offers a more patient-friendly oral administration without an initial hormonal flare, providing a faster onset of action and improved treatment adherence.
The Phase 2 clinical trial of Merigolix in uterine fibroids was conducted by TiumBio's partner, Daewon Pharmaceutical, and enrolled a total of 71 women diagnosed with uterine fibroids. Participants were randomly assigned to receive high, medium, or low doses of Merigolix, or placebo, administered orally once daily for 12 weeks, followed by a 12-week observation period. The results showed that Merigolix led to statistically significant improvements in heavy menstrual bleeding (HMB)—a validated clinical endpoint—across all dosage groups compared to the placebo.
In addition to the primary endpoint, Merigolix demonstrated statistically and clinically meaningful improvements in several key secondary endpoints, including fibroid size reduction, increased hemoglobin levels (indicating improved anemia), and relief of pelvic pain. The safety and tolerability profile of Merigolix was consistent with prior clinical data, with no new safety signs.
The mechanism of action of Merigolix can be used in various disorders, including endometriosis, uterine fibroids, ART, precocious puberty, and prostate cancer. Notably, in a separate Phase 2 clinical trial for endometriosis completed in 2024, Merigolix also showed excellent therapeutic efficacy and safety, further reinforcing its potential as a promising new treatment.
"We are very excited that Merigolix has demonstrated excellent therapeutic efficacy not only in endometriosis but also in uterine fibroids," said Hun-Taek Kim, Ph.D., MBA, CEO of TiumBio. "successfully achieving both efficacy and safety in Phase 2 significantly increases the probability of regulatory approval and licensing opportunities. We plan to accelerate development and expand into the global uterine fibroid treatment market," he added.
"Uterine fibroids are a condition that causes significant suffering for many women, and we believe Merigolix has the potential to become an important new oral treatment that addresses this unmet medical need," said Jonathan In Baek, President of Daewon Pharmaceutical. "We are pleased with the positive results in uterine fibroids and will continue our efforts to provide patients with a convenient and effective new treatment option," he continued.
Uterine fibroids are benign tumors that develop in the uterus, primarily affecting women of reproductive age, particularly those in their 30s and older. The condition has a high prevalence rate of approximately 20% among women over the age of 35. The most common symptom is heavy menstrual bleeding, but it can also cause abnormal uterine bleeding, pelvic pain, and anemia.
Meanwhile, TiumBio entered into a licensing agreement with Daewon Pharmaceutical in 2019, granting Daewon the rights to develop and commercialize Merigolix in South Korea.
About TiumBio Co., Ltd.
TiumBio (KRX: 321550.KQ) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for patients with rare and incurable diseases. Its mission is to expand the hope and happiness of mankind through our science. TiumBio has three leading pipeline assets: Merigolix (code name: TU2670), TU2218, and TU7710, all in various stages of clinical development.
Merigolix is a once-daily, oral GnRH receptor antagonist being developed for the treatment of endometriosis, uterine fibroids, and assisted reproductive technology. TU2218 is a first-in-class oral immune-oncology therapy targeting TGF-β and VEGF pathways to promote response rates in cancer patients when used in combination with immune checkpoint inhibitors. TU7710 is a novel rFVIIa designed to extend its half-life in order to provide more clinical benefits to hemophilia patients with inhibitors.
With its expertise in drug development, TiumBio is committed to the discovery and development of innovative treatments to ease the burden of debilitating diseases. For further information, visit our website at www.tiumbio.com/en and connect with us on LinkedIn.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
an hour ago
- Korea Herald
Firebolt Expands in APAC with Singapore Hub, Appoints Deepak Ajmani to Lead Regional Growth
PALO ALTO, Calif., Aug. 20, 2025 /PRNewswire/ -- Firebolt, the analytical database for real-time applications, today announced a major expansion across APAC, driven by unprecedented demand from organizations accelerating their data and AI initiatives. As part of this growth, Firebolt has opened a new regional hub in Singapore to strengthen its presence across the region. To lead this effort, Firebolt has appointed Deepak Ajmani as Head of Asia & ANZ. With over 20 years of leadership experience in the technology industry — including senior roles at Oracle, Dell, Google, and most recently as Vice President of A/NZ & Emerging Markets at Confluent — Deepak brings a deep understanding of enterprise data and cloud strategies, along with a proven track record of scaling go-to-market teams across APAC. His appointment deepens Firebolt's presence while accelerating growth in key verticals like financial services, e-commerce, and technology. Firebolt was built for engineers running mission-critical analytics and AI workloads, delivering strong price/performance even for complex, high-concurrency demands. With Postgres SQL compatibility and native Iceberg support, Firebolt runs low-latency analytics, scalable batch ELT, and AI workloads efficiently. "Organizations across APAC are pushing the limits of analytics and AI workloads," said Deepak Ajmani. "Firebolt's ability to process massive volumes of data at low latency and high concurrency — all while optimizing for cost — is a game-changer. I'm excited to partner with forward-thinking companies across the region to unlock new possibilities with Firebolt." As investment in AI-driven analytics, cloud infrastructure, and cost-optimized data platforms accelerates across the region, Firebolt's expansion comes at a pivotal moment. Earlier this year, Firebolt launched operations in Bangalore and has since made several key executive hires, underscoring the company's momentum across the region. "We're seeing demand in APAC accelerate faster than in any other market we've entered," said Sandeep Mathur, Managing Director of APAC. "With Deepak joining the team, we're well-positioned to meet the region's surging need for analytical infrastructure that can power the next generation of real-time applications." "Our mission is to give engineers an analytical database that delivers unmatched performance, flexibility, and control," added Hemanth Vedagarbha, President at Firebolt. "Deepak's track record in scaling high-performing businesses and teams will be instrumental as we enter our next phase of growth, ensuring we deliver greater efficiency and value across the region." This expansion reinforces Firebolt's leadership in enabling low-latency analytics, high-concurrency performance, and AI-ready capabilities for organizations across a wide range of industries. About Firebolt Firebolt is the analytical database for real-time applications. Built for production-grade data and AI workloads, Firebolt gives engineers the performance, flexibility, and control they need. Firebolt has Postgres-compatible SQL, can run on Iceberg, and delivers unmatched price-performance even on complex, high-concurrency workloads. Whether fully managed in the cloud or self-hosted, Firebolt runs low-latency queries, complex joins, and heavy batch ELT efficiently in one place. For more information, visit and follow on LinkedIn.
Korea Herald
11 hours ago
- Korea Herald
Delska's New 10MW Data Center in Latvia Achieves Tier III Design Certification
RIGA, Latvia, Aug. 19, 2025 /PRNewswire/ -- Northern European data center operator Delska's upcoming facility, EU North Riga LV DC1, has been awarded the prestigious Uptime Institute Tier III Design Certification—an important milestone ahead of its planned launch at the end of this year. Once operational, it will be one of the greenest data centers in the Baltic region. The Tier III Design certification ensures the facility meets strict standards for redundancy, safety, and uninterrupted service, guaranteeing 99.982% uptime. "In a world where even a few seconds of downtime can cost thousands, Tier III means our infrastructure stays online—even during planned maintenance," said Delska CEO Andris Gailitis. Addressing power shortages in major European hubs, the 10 MW site, offering up to 250 kW per rack, is built for next-generation workloads, including AI and high-performance computing (HPC). Its modular 6,000 m² layout is fully scalable, with the ability to expand the data center campus site up to 30 MW. Sustainability is at the core of the design. The facility will run entirely on 100% wind energy, with backup generators powered by Neste MY renewable diesel. Targeting a PUE of just 1.3, it will use advanced free-cooling systems, hot-aisle containment, an effective Weiss Technik wall cooling system and Trane Turbocor-based chillers. It supports both air cooling and high-density direct-to-chip cooling. Delska also aims for LEED green building certification, an achievement held by fewer than 15 buildings in Latvia. Upon completion, LV DC1 will undergo Tier III Facility certification to confirm its construction and operations meet the same high standard as its design. This will be Delska's third Tier III-certified data center and sixth overall, joining two Tier III Facility-certified sites in Lithuania. Plans include an additional Lithuanian data center and another facility in the region, strengthening Delska's Baltic data centers' network. About Delska Delska is one of the largest data center operators in the Baltics, with over 26 years in IT and network infrastructure. Operating fully green Tier III and PCI-DSS certified facilities in Riga and Vilnius with 19 MW capacity, Delska also maintains points of presence in Frankfurt, Amsterdam, and Stockholm. Its portfolio includes cloud, server rental, network, security, and managed services. Since being acquired by Quaero European Infrastructure Fund II in 2020, Delska has significantly expanded its infrastructure and improved energy efficiency. In 2024, DEAC (Latvia) and DLC (Lithuania) merged under a new Delska brand, and this year RackRay (Lithuania) joined the group of companies.
Korea Herald
12 hours ago
- Korea Herald
Rockwell Automation Report Finds CPG Industry Prioritizing Innovation Over Cost-Cutting
Research shows CPG leaders are investing in AI and talent to stay competitive MILWAUKEE, Aug. 19, 2025 /PRNewswire/ -- Rockwell Automation, Inc. (NYSE: ROK), the world's largest company dedicated to industrial automation and digital transformation, today announced the results of the 10th annual State of Smart Manufacturing Report: Consumer Packaged Goods (CPG) Edition. The findings highlight how manufacturers are placing greater importance on innovation, workforce development, and long-term growth strategies. The CPG industry is facing pressure on multiple fronts, from the growth of store brands to the demand for faster innovation and more sustainable products. At the same time, consumer loyalty is harder to earn, and expectations for customization and transparency are rising. In response to this, CPG companies are moving away from small-scale technology pilots and investing in solutions that deliver measurable results across the organization. The combination of workforce training, better use of data, and more adaptable systems is helping these manufacturers stay competitive while managing complexity. And as private-label brands expand and consumer expectations evolve, CPG leaders are prioritizing investments that help them compete more effectively in a crowded and fast-changing market. Notable Key Trends from 2024 to 2025: Rising Competition Leads Industry Concerns: In 2024, economic uncertainty and inflation were main challenges noted in our annual survey. In 2025, competition has taken the lead, driven by increased market pressure from private-label products and changing consumer buying habits. Technology Needs to Work for People: Companies are focusing less on simply adopting new tools and more on making sure new technology fits their teams and operations. Usability and scalability are now critical factors in technological decisions. Capabilities CPG leaders are looking for in their workforce include: communications/teamwork (86%), adaptability/flexibility (85%), while analytical thinking and cybersecurity practices are tied (84%). AI and Robotics Lead Investment Priorities: At the heart of technology investment decisions is a shift in thinking. 70% of CPG manufacturers say they are investing in AI, robotics, and simulation technologies for long-term business growth. This is a shift from last year when technology supported more sales analytics and process optimization. More companies are using data effectively The number of manufacturers who say they are using their data to guide decision-making is up from 40% in 2024 to 44% in 2025. AI is playing a growing role in data utilization in key areas like quality control, logistics, and cybersecurity, scoring 5% above the general average. Workforce strategies are evolving While 2024 emphasized attracting skilled labor, the 2025 report shows 34% of manufacturers are concentrating more on training current employees on updated processes, while 33% of the focus is on managing change effectively and improving employee retention. "CPG manufacturers are no longer just reacting to disruption—they're proactively investing in technologies that deliver sustainable growth and competitive advantage," said Steve Deitzer, vice president, Global Industry, CPG, Rockwell Automation. "This year's report shows a clear pivot toward long-term thinking, where AI, automation, and workforce enablement are central to success." Scalability and integration are now central to how CPG leaders approach growth. By aligning technology, people and processes, companies are working to build more agile and efficient operations that can keep up with market changes. The 2025 State of Smart Manufacturing Report, based on insights from 174 CPG leaders across 15 countries, is part of Rockwell Automation's broader global research initiative surveying over 1,500 manufacturing decision-makers. The full findings of the report can be found here.
